ctDNA to Predict Treatment Response in Head and Neck Squamous Cell Carcinoma: A Systematic Review
The Laryngoscope · 2026-01 · 136 (1) · 50-62
DOI: 10.1002/lary.32440 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Laryngoscope, online erschienen am 17.07.2025. Verfasst von Oliver Jones und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Student, School of Medicine and Biomedical Sciences, Medical Sciences Division, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
To investigate the potential role of plasma circulating tumor DNA (ctDNA) in predicting treatment response in HPV‐positive and HPV‐negative Head and Neck Squamous Cell Carcinoma (HNSCC). Data Sources Medline, PubMed, Cochrane databases (Cochrane Library, Cochrane Central Register of Controlled Trials) and EMBASE databases were searched in accordance with the standard PICOTS model. Review Methods Search results were independently reviewed by two primary authors. Disagreements were adjudicated by the senior author. Studies were excluded according to defined exclusion criteria. Studies were assessed for quality in accordance with the REMARK guidelines. Data were then extracted, and findings were discussed narratively.
Results
From a total of 1026 articles initially retrieved, 18 papers were included in the final review. Study quality was suboptimal, with a median REMARK score of 12.65/20. Short follow‐up (median 24.5 months) and modest cohort sizes (median 59 patients) were observed. Most studies (13/18) investigated HPV ctDNA alone, and ctDNA detection methods varied considerably between studies. Broadly, studies showed that ctDNA monitoring has a high negative predictive value (91.7%) for residual and recurrent disease. Persistently positive ctDNA corresponded with poorer outcomes overall, but there was variability in the positive predictive value between studies, which was mitigated by consecutive testing.
Conclusion
These results suggest there is potential for ctDNA utility in surveillance for both HPV‐positive and HPV‐negative HNSCC patients; however, better adherence to reporting guidelines will enable meta‐analysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Student, School of Medicine and Biomedical Sciences, Medical Sciences Division, University of Oxford, Oxford, UK.
- Consultant Head and Neck Surgeon, Blenheim Head and Neck Unit, Oxford University NHS Foundation Trust, Oxford, UK.
- Consultant Head and Neck Surgeon, Nuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, UK.
ORCID-Profile: Oliver Jones, Sumrit Bola
Zitieren
APA
Jones, O., Bola, S., & Winter, S. C. (2026). ctDNA to Predict Treatment Response in Head and Neck Squamous Cell Carcinoma: A Systematic Review. The Laryngoscope, 136(1), 50-62. https://doi.org/10.1002/lary.32440
Vancouver
Jones O, Bola S, Winter SC. ctDNA to Predict Treatment Response in Head and Neck Squamous Cell Carcinoma: A Systematic Review. The Laryngoscope. 2026;136(1):50-62. doi:10.1002/lary.32440
BibTeX
@article{Jones2026,
author = {Jones, Oliver and Bola, Sumrit and Winter, Stuart C},
title = {ctDNA to Predict Treatment Response in Head and Neck Squamous Cell Carcinoma: A Systematic Review},
journal = {The Laryngoscope},
year = {2026},
volume = {136},
number = {1},
pages = {50--62},
doi = {10.1002/lary.32440}
}
EUVIMED